MissBruna Giribaldi Cunha
Honorary Research Officer
Department of Brain Sciences - Faculty of Medicine
- Honorary Research OfficerDepartment of Brain Sciences - Faculty of Medicine
- 020 7594 7992 (Work)
- Medical Sciences, Commonwealth Building, Hammersmith Campus, United Kingdom
RESEARCH
Research Overview
Publications:
1) Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R. Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine. 2022 Apr;28(4):844-851. doi: 10.1038/s41591-022-01744-z. Epub 2022 Apr 11. PMID: 35411074.
2) Carhart-Harris, R. L.*, Giribaldi B* (co-first author), Watts R*, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. (2021) Trial of Psilocybin versus Escitalopram for major depression. New England Journal of Medicine. 385: 1402-1411. doi: 10.1056/NEJMoa2032994. PMID: 33852780.
3) Barba T, Kettner H, Radu C, Peill JM, Roseman L, Nutt DJ, Erritzoe D, Carhart-Harris R, Giribaldi B (Lead last author). Psychedelics and sexual functioning: a mixed-methods study. Sci Rep. 2024 Feb 7;14(1):2181. doi: 10.1038/s41598-023-49817-4. PMID: 38326446; PMCID: PMC10850066.
4) Weiss B, Ginige I, Shannon L, Giribaldi B, Murphy-Beiner A, Murphy R, Baker-Jones M, Martell J, Nutt DJ, Carhart-Harris RL, Erritzoe D. Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychol Med. 2024 Jan;54(1):178-192. doi: 10.1017/S0033291723001514. Epub 2023 Jun 2. PMID: 37264814; PMCID: PMC10692311.
5) Barba T, Buehler S, Kettner H, Radu C, Cunha BG, Nutt DJ, Erritzoe D, Roseman L, Carhart-Harris R. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. BJPsych Open. 2022 Sep 6;8(5):e163. doi: 10.1192/bjo.2022.565. PMID: 36065128; PMCID: PMC9534928.
6) Nayak SM, Bari BA, Yaden DB, Spriggs MJ, Rosas FE, Peill JM, Giribaldi B, Erritzoe D, Nutt DJ, Carhart-Harris R. A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression. Psychedelic Med (New Rochelle). 2023 Mar;1(1):18-26. doi: 10.1089/psymed.2022.0002. Epub 2022 Oct 28. PMID: 37337526; PMCID: PMC10278160.
7) Weiss B, Erritzoe D, Giribaldi B, Nutt DJ, Carhart-Harris RL. A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression. J Psychopharmacol. 2023 Jul;37(7):717-732. doi: 10.1177/02698811231167848. Epub 2023 Apr 25. PMID: 37122239; PMCID: PMC10350722.
8) Spriggs MJ, Giribaldi B, Lyons T, Rosas FE, Kärtner LS, Buchborn T, Douglass HM, Roseman L, Timmermann C, Erritzoe D, Nutt DJ, Carhart-Harris RL. Body mass index (BMI) does not predict responses to psilocybin. J Psychopharmacol. 2023 Jan;37(1):107-116. doi: 10.1177/02698811221131994. Epub 2022 Nov 14. PMID: 36373934; PMCID: PMC9834321.
9) Murphy R, Kettner H, Zeifman R, Giribaldi B, Kartner L, Martell J, Read T, Murphy-Beiner A, Baker-Jones M, Nutt D, Erritzoe D, Watts R, Carhart-Harris R. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. Front Pharmacol. 2022 Mar 31;12:788155. doi: 10.3389/fphar.2021.788155. PMID: 35431912; PMCID: PMC9009076.
10) Copa D, Erritzoe D, Giribaldi B, Nutt D, Carhart-Harris R, Tagliazucchi E. Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. J Affect Disord. 2024 May 15;353:60-69. doi: 10.1016/j.jad.2024.02.089. Epub 2024 Feb 27. PMID: 38423367.
11) Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ. “Psilocybin with Psychological Support for Treatment-Resistant Depression: Six-Month Follow-Up.” Psychopharmacology, Aug. 2017, doi: 10.1007/s00213-017-4771-x. Epub 2017 Nov 8. PMID: 29119217; PMCID: PMC5813086.
12) Kaelen M, Giribaldi B, et al. “The Hidden Therapist: Evidence for a Central Role of Music in Psychedelic Therapy”. Psychopharmacology (2018) 235:505.
Publications:
1) Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R. Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine. 2022 Apr;28(4):844-851. doi: 10.1038/s41591-022-01744-z. Epub 2022 Apr 11. PMID: 35411074.
2) Carhart-Harris, R. L.*, Giribaldi B* (co-first author), Watts R*, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. (2021) Trial of Psilocybin versus Escitalopram for major depression. New England Journal of Medicine. 385: 1402-1411. doi: 10.1056/NEJMoa2032994. PMID: 33852780.
3) Barba T, Kettner H, Radu C, Peill JM, Roseman L, Nutt DJ, Erritzoe D, Carhart-Harris R, Giribaldi B (Lead last author). Psychedelics and sexual functioning: a mixed-methods study. Sci Rep. 2024 Feb 7;14(1):2181. doi: 10.1038/s41598-023-49817-4. PMID: 38326446; PMCID: PMC10850066.
4) Weiss B, Ginige I, Shannon L, Giribaldi B, Murphy-Beiner A, Murphy R, Baker-Jones M, Martell J, Nutt DJ, Carhart-Harris RL, Erritzoe D. Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychol Med. 2024 Jan;54(1):178-192. doi: 10.1017/S0033291723001514. Epub 2023 Jun 2. PMID: 37264814; PMCID: PMC10692311.
5) Barba T, Buehler S, Kettner H, Radu C, Cunha BG, Nutt DJ, Erritzoe D, Roseman L, Carhart-Harris R. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. BJPsych Open. 2022 Sep 6;8(5):e163. doi: 10.1192/bjo.2022.565. PMID: 36065128; PMCID: PMC9534928.
6) Nayak SM, Bari BA, Yaden DB, Spriggs MJ, Rosas FE, Peill JM, Giribaldi B, Erritzoe D, Nutt DJ, Carhart-Harris R. A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression. Psychedelic Med (New Rochelle). 2023 Mar;1(1):18-26. doi: 10.1089/psymed.2022.0002. Epub 2022 Oct 28. PMID: 37337526; PMCID: PMC10278160.
7) Weiss B, Erritzoe D, Giribaldi B, Nutt DJ, Carhart-Harris RL. A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression. J Psychopharmacol. 2023 Jul;37(7):717-732. doi: 10.1177/02698811231167848. Epub 2023 Apr 25. PMID: 37122239; PMCID: PMC10350722.
8) Spriggs MJ, Giribaldi B, Lyons T, Rosas FE, Kärtner LS, Buchborn T, Douglass HM, Roseman L, Timmermann C, Erritzoe D, Nutt DJ, Carhart-Harris RL. Body mass index (BMI) does not predict responses to psilocybin. J Psychopharmacol. 2023 Jan;37(1):107-116. doi: 10.1177/02698811221131994. Epub 2022 Nov 14. PMID: 36373934; PMCID: PMC9834321.
9) Murphy R, Kettner H, Zeifman R, Giribaldi B, Kartner L, Martell J, Read T, Murphy-Beiner A, Baker-Jones M, Nutt D, Erritzoe D, Watts R, Carhart-Harris R. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. Front Pharmacol. 2022 Mar 31;12:788155. doi: 10.3389/fphar.2021.788155. PMID: 35431912; PMCID: PMC9009076.
10) Copa D, Erritzoe D, Giribaldi B, Nutt D, Carhart-Harris R, Tagliazucchi E. Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. J Affect Disord. 2024 May 15;353:60-69. doi: 10.1016/j.jad.2024.02.089. Epub 2024 Feb 27. PMID: 38423367.
11) Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ. “Psilocybin with Psychological Support for Treatment-Resistant Depression: Six-Month Follow-Up.” Psychopharmacology, Aug. 2017, doi: 10.1007/s00213-017-4771-x. Epub 2017 Nov 8. PMID: 29119217; PMCID: PMC5813086.
12) Kaelen M, Giribaldi B, et al. “The Hidden Therapist: Evidence for a Central Role of Music in Psychedelic Therapy”. Psychopharmacology (2018) 235:505.